Founded in 1998, Hybio is a high-tech enterprise specializing in R&D and manufacturing of diverse peptide products, growing into a leading peptide pharmaceutical company and the first of its kind to go public in China (2011, stock code 300199). The company offers a full range of peptide products (API and finished dosage forms) and services (CRO and CDMO), with peptide finished products mainly sold domestically and peptide APIs supplied worldwide, and its Shenzhen headquarters has passed local and national NMPA GMP inspections more than 90 times.

Chưa có bình luận nào.
Để lại đánh giá & nhận xét